US equities |
NVDA $239.94 ▲+2.56% SPCX $169.42 ▲+6.58% MU $1,063.13 ▼-1.09% TSLA $380.07 ▲+2.56% SNDK $1,704.68 ▼-0.89% MSFT $528.45 ▲+2.11% INTC $116.06 ▼-2.74% META $742.93 ▲+2.04%
FinancialContent

Aquestive Therapeutics, Inc. - Common Stock (NQ:AQST)

4.565 +0.015 (+0.33%)
Delayed Quote Updated: 3:38 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aquestive Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Investor Notice: Robbins LLP Informs Investors of the Aquestive Therapeutics, Inc. Class Action Lawsuit
From Robbins LLP
Via Business Wire
News headline image
Aquestive (AQST) Q4 2025 Earnings Call Transcript ↗
Aquestive (AQST) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings Lawsuit
Aquestive Therapeutics Inc (NASDAQ:AQST) Reports Mixed Q4 2025 Results and Anaphylm Regulatory Update ↗
Via Chartmill
News headline image
Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
AQST SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Aquestive Therapeutics to Participate in Upcoming March Investor Conferences
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics to Present New Clinical Data on Anaphylm™ (dibutepinephrine) Sublingual Film at the 2026 AAAAI Annual Meeting
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
AQST INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Aquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt as Chief Medical Officer
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
AQST SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aquestive Therapeutics, Inc. - AQST
From Pomerantz LLP
Via GlobeNewswire
Top movers in Monday's session ↗
Via Chartmill
Check out the stocks that are attracting the most attention and driving market activity. ↗
Via Chartmill
News headline image
AQST Investors Have Opportunity to Join Aquestive Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Monday's session: top gainers and losers ↗
Via Chartmill
Monday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
Why Did AQST Stock Jump 35% Today? ↗
The company received a Complete Response Letter from the U.S. Food and Drug Administration for its New Drug Application seeking approval of Anaphylm, a sublingual film to treat severe Type I allergic... 
Via Stocktwits
Monday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm™
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aquestive Therapeutics, Inc. - AQST
From Pomerantz LLP
Via GlobeNewswire
News headline image
AQST INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
AQUESTIVE ALERT: Bragar Eagel & Squire, P.C. is Investigating Aquestive Therapeutics, Inc. on Behalf of Aquestive Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aquestive Therapeutics, Inc. - AQST
From Pomerantz LLP
Via GlobeNewswire
News headline image
Kaplan Fox & Kilsheimer LLP is Investigating Aquestive Therapeutics, Inc. (AQST) for Potential Securities Law Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Kaplan Fox &amp; Kilsheimer LLP is Investigating Aquestive Therapeutics, Inc. (AQST) for Potential Securities Law Violations
Via TheNewswire.com
News headline image
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >